ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema.

L, Kodjikian; A, Lecleire-Collet; C, Dot; Lez ML, Le; S, Baillif; A, Erginay; E, Souied; E, Fourmaux; P, Gain; A, Ponthieux

doi:10.2147/opth.s313081

Public

ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema.

Shared by NobleBlocks on Jun 3, 2021 • 12:00 AM UTC

Authors:

Kodjikian L

Lecleire-Collet A

Dot C

Abstract

Purpose To evaluate the real-world effectiveness of intravitreal ranibizumab 0.5 mg (Lucentis) in improving visual acuity (VA) in adults with decreased VA due to diabetic macular edema (DME).Patients and methods Real-world prospective observational 24-month study. Ranibizumab-naïve patients (n=116) ...

Subject

Induction

Visual acuity

Switch

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!